More on Teva (TEVA) Q3: swings to net loss of $79M from profit of $916M last year, due to $670M...

More on Teva (TEVA) Q3: swings to net loss of $79M from profit of $916M last year, due to $670M provision connected to patent litigation and $481M impairment mostly related to R&D. U.S. sales +33% to $2.6B, boosted by the acquisition of Cephalon. Europe sales +13% in local currencies. Copaxone revenue +13% to $1.05B. Narrows 2012 guidance range to $5.32-$5.38 for EPS and $20.1B-$20.7B for revenue, both in line.

From other sites
Comments (3)
  • doc47
    , contributor
    Comments (1835) | Send Message
    Gee, nothing great here. Oh well, more covered calls until the greater fool comes along to take the stock away.
    1 Nov 2012, 09:38 AM Reply Like
  • Desperado2012
    , contributor
    Comments (98) | Send Message
    Are these numbers even real? I thought Teva was reporting tomorrow 11-02-12.
    1 Nov 2012, 09:58 AM Reply Like
  • Dgbinns
    , contributor
    Comments (4) | Send Message
    is Teva really that bad? It is performing 3% higher than my BDX since I purchased both at relatively the same time at 8%. Maybe my expectations are too low.
    1 Nov 2012, 06:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs